4:51 PM
 | 
Jan 03, 2013
 |  BC Extra  |  Clinical News

Nexavar meets PFS endpoint in Phase III thyroid cancer trial

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) and partner Bayer AG (Xetra:BAYN) said twice-daily oral Nexavar sorafenib met the primary endpoint of improving progression-free survival (PFS) vs. placebo in the Phase...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >